A novel multivalent OspA vaccine against Lyme borreliosis shows promise in Phase I/II studies

Expert Rev Vaccines. 2013 Sep;12(9):973-5. doi: 10.1586/14760584.2013.824704.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Bacterial / blood
  • Antigens, Bacterial / immunology
  • Antigens, Surface / administration & dosage*
  • Antigens, Surface / adverse effects
  • Antigens, Surface / immunology*
  • Bacterial Outer Membrane Proteins / administration & dosage*
  • Bacterial Outer Membrane Proteins / adverse effects
  • Bacterial Outer Membrane Proteins / immunology*
  • Bacterial Vaccines / administration & dosage*
  • Bacterial Vaccines / adverse effects
  • Bacterial Vaccines / immunology*
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Humans
  • Lipoproteins / administration & dosage*
  • Lipoproteins / adverse effects
  • Lipoproteins / immunology*
  • Lyme Disease / immunology
  • Lyme Disease / prevention & control*

Substances

  • Antibodies, Bacterial
  • Antigens, Bacterial
  • Antigens, Surface
  • Bacterial Outer Membrane Proteins
  • Bacterial Vaccines
  • Lipoproteins
  • OspA protein